News|Videos|August 20, 2025

Allegheny General Hospital's Support of the Health System's Transplant Program

Deeksha Jandhyala, MD, discusses how her team works to prevent infections and provide clinical assistance for transplant candidates.

We are continuing our new series, Media Day, where we spotlight individual medical institutions and infectious disease (ID) programs. Today, we spotlight the Allegheny Health Network (AHN) in Pittsburgh, Pennsylvania.

Allegheny General Hospital in Pittsburgh, Pennsylvania, the flagship hospital within the Allegheny Health Network (AHN), has a storied history within surgery, especially as it relates to heart procedures.

One of its physicians, George Magovern, MD, was a pioneer in surgical techniques including open-heart procedures. Magovern partnered with Edward Kent, MD, a nationally recognized chest surgeon, introduced to the area the very first open-heart procedures using the heart-lung machine.1

Magovern also partnered with a local engineer, Harry Cromie, to develop a revolutionary sutureless prosthetic aortic valve designed to shorten operative times and improve patient outcomes. This led to greater survival rates for these procedures.1 In 1963, Magovern performed the world’s second left single lung transplant in a man dying of emphysema.1 Today, AHN continues to offer an array of different transplants including heart, liver, kidney, pancreas, stem cell/chimeric antigen receptor T-cell transplants, and left ventricular assist device procedures.

Deeksha Jandhyala, MD, an infectious diseases (ID) specialist with the AHN Medicine Institute and medical director of transplant infectious diseases at Allegheny General Hospital, noted that the transplant department recently reached a milestone of performing its 500th heart transplant.

Behind the scenes, there is much to consider before transplant candidates are approved for such procedures. One of these significant steps is when Jandhyala and her team screen them for infections. They support their transplant program by seeing transplant candidates through the surgical cycle. They treat a broad array of diseases caused by microorganisms and manage infectious diseases in patients pre- and post transplant.

“Most of our transplant candidates come to this transplant ID clinic to get their regular, routine infectious disease screening,” Jandhyala said. “We screen for latent infections. We try to capture these patients in the outpatient setting before their transplant so that we can mitigate their infectious risk. We also follow them on the posttransplant side, and if they are getting active treatment for their infection.”

She mentors trainees and junior faculty members, in addition to overseeing protocols that go into their solid organ transplant guidelines. Her team works closely with other medical teams.

“We have a really close collaborative relationship with our transplant surgical teams,” Jandhyala said. “We sit in on multidisciplinary rounds...We help them design a treatment plan.”

In the next episode, Thomas Walsh, MD, discusses AHN's approach to antibiotic stewardship.


Reference
1. History. AHN. Accessed August 20, 2025.
https://www.ahn.org/locations/hospitals/allegheny-general/patients-visitors/magovern-conference-center/history

Related to this article

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.